Highest-materiality recent filing
RadNet Q2 revenue up 25% to $622.7M, raises FY2026 guidance
Q2 revenue $622.7M (+25% YoY); Adjusted EBITDA $99.7M (+22.7%); net income $7.5M vs $14.5M.
RadNet announces proposed $200M incremental term loan for acquisitions and growth
Seeks $200 million incremental term loan under existing credit agreement, maturing April 18, 2031.
RadNet Q1 revenue $575.6M (+22.1%), adj. EBITDA $63.3M (+36.3%); raises FY guidance
Total Revenue $575.6M, up 22.1% YoY; Adjusted EBITDA $63.3M, up 36.3% YoY.
RadNet acquires Gleamer for up to €230M; DeepHealth becomes largest radiology AI provider
All-cash deal includes ~€215M closing payment and up to €15M milestone-based contingent payment.
RadNet Q4 revenue $547.7M record; Adj. EBITDA $87.7M record; issues 17-22% growth guide for 2026
Q4 2025 revenue $547.7M (+14.8% YoY); Adj. EBITDA $87.7M (+16.9% YoY) - both quarterly records.
RadNet Q3 revenue $522.9M (+13.4% YoY), adj. EBITDA $84.9M (+15.2%), raises FY2025 guidance
Total revenue $522.9M vs $461.1M a year ago; adjusted EPS $0.20 (up from $0.18).
RadNet Q2 revenue $498.2M (+8.4% YoY), record Adj. EBITDA $81.2M; raises FY2025 guidance
Q2 revenue $498.2M (+8.4% YoY), Adjusted EBITDA $81.2M (record, +12.3%), margin up 57bps to 16.3%.
RadNet completes iCAD acquisition via DeepHealth subsidiary; expands AI breast health
DeepHealth, RadNet's digital health segment, closed acquisition of iCAD (NASDAQ: ICAD).
RadNet Q1 revenue up 9.2% to $471M, net loss $37.9M; raises 2025 revenue and EBITDA guidance
Revenue $471.4M (+9.2% YoY); Adjusted EBITDA $46.4M (-20.6% YoY) hit by $22M revenue and $15M EBITDA from SoCal wildfires and winter weather.
RadNet to acquire iCAD for ~$103M all-stock; ~98% premium
All-stock acquisition of iCAD for ~$103M (0.0677 RDNT shares per ICAD share); ~98% premium to ICAD's April 14 close.
RadNet Q4 revenue $477M (+13.5%), Adj EBITDA $75M record; FY2025 guidance issued
Q4 revenue $477.1M (+13.5% y/y), Adjusted EBITDA $75.0M (+14.0%), both quarterly records.
RadNet amends credit facility, reducing interest rates by 0.25% on $872.8M term loans
Interest rate on term loans reduced to Term SOFR + 2.25% or base rate + 1.25%.
RadNet reports record Q3 revenue $461.1M (+14.7%), raises 2024 guidance
Revenue $461.1M (+14.7% YoY); Adj. EBITDA $73.7M (+27.2%); adjusted EPS $0.18 vs $0.13.
RadNet Digital Health segment revenue up 34% in H1 2024; AI revenue grows 128% YoY
Full-year Digital Health revenue guidance of $60-70M with adjusted EBITDA of $13-15M.
RadNet appoints Kees Wesdorp as President & CEO of Digital Health segment effective Oct 1, 2024
Wesdorp will lead eRAD, DeepHealth OS and AI solutions under the Digital Health division.
RadNet Q2 revenue $459.7M (+13.9% YoY), adj. EBITDA $72.3M (+19.7%), raises FY2024 guidance
Adjusted diluted EPS $0.16 vs $0.10 YoY; GAAP net loss $3.0M due to $8.8M debt refinancing costs.
RadNet Q1 revenue $431.7M (+10.5% YoY); adjusted EBITDA $58.5M (+21.4%); raises 2024 guidance
Q1 net loss $(0.04)/share vs $(0.36) last year; adjusted EPS $0.07 vs $(0.22).
RadNet closes $875M term loan and $282M revolver refinancing, extends maturities
New $875M senior secured term loan matures April 2031; revolver of $282M matures April 2029.
RadNet prices $875M term loan and $282M revolver in upsized refinancing
$875M term loan (up from $840M) at SOFR+2.50%, 7-yr maturity; $282M revolver (up from $250M), 5-yr term.
RadNet proposes $840M term loan and $250M revolver to refinance existing debt, add $148M for growth
RadNet plans $840M term loan (7-yr) and $250M revolver (5-yr), replacing $679M due 2028 and $195M due 2026.
RadNet closes $230.2M common stock offering (5.23M shares at $44.00/share)
Closed public offering of 5,232,500 shares at $44.00/share, including full exercise of underwriters' option for 682,500 additional shares.
RadNet Q4 revenue record $420.4M (+9.5%), Adj. EBITDA $65.8M (+15%); guides 2024 higher
Q4 revenue $420.4M (+9.5% YoY); Imaging Center revenue $415.3M (+8.6%); total Adj. EBITDA $65.8M (+15%)
RadNet Q3 revenue up 14.8% to $402M; raises 2023 Adj. EBITDA guidance to $235M-$245M
Revenue $402M (+14.8% YoY); Imaging-Center segment revenue $399.1M (+14.3%); procedural volumes +8.6% aggregate, +4.2% same-center.
Imaging Center segment revenue $401.3M (+13.8% YoY); consolidated revenue $403.7M (+13.9%).
RadNet closes upsized public offering of 8.7M shares for ~$259M gross proceeds
Sold 8,711,250 shares at $29.75 per share, including full overallotment of 1,136,250 shares.
RadNet Q1 revenue rises 14% to $391M; raises full-year guidance for revenue and EBITDA
Revenue $390.6M, +14.3% YoY; Imaging Center segment $388.4M, +13.9%.
RadNet Q4 revenue $383.9M (+15.2% YoY); 2023 guidance projects 7-10% revenue growth
Imaging Center segment revenue $382.5M (+15.1% YoY); Adjusted EBITDA $61.6M (+18.4% YoY).
RadNet Q3 revenue up 5.2% to $350M; Adj EBITDA down 8.5%; guides FY 2022 lower
Imaging Centers Adj EBITDA $50.2M vs $54.9M YoY, down 8.5% on labor costs/shortage.
RadNet Q2 2022 revenue up 6.1% to $354.4M; reaffirms full-year guidance
Revenue $354.4M (+6.1% YoY); Imaging Centers revenue $352.8M (+5.7%).
RadNet Q1 revenue $341.8M, adj EBITDA $41.7M; raises 2022 guidance
Revenue $341.8M (+8.4%); imaging centers $341.2M (+8.2%).
RadNet Q4 revenue $333.2M (+8% YoY), GAAP EPS -$0.07; guides 2022 Adj EBITDA $205-215M ex-AI losses
Q4 revenue $333.2M (+8.0% YoY), Adj EBITDA $54.5M (+7.5%), Adj EPS $0.13 vs $0.20 YoY.
RadNet acquires Aidence and Quantib, outlines AI strategy for cancer screening and operations
Acquired Aidence (AI for lung cancer screening) and Quantib (AI for prostate MRI) to bolster AI portfolio.
RadNet acquires AI firms Aidence and Quantib for ~$95M combined; issues 2.1M shares
Aidence acquired for ~$50M (incl. $10M milestones); Quantib for ~$45M.
On September 11, 2024 RadNet, Inc. (“RadNet”) appointed Cornelis “Kees” Wesdorp, age 47, to serve as President and Chief Executive Officer of its Digital Health segment (“Digital Health”), which includes RadNet’s eRad and Artificial Intelligence businesses, effective October 1, 2024.
On August 4, 2023, the Company appointed Dr. Gregory Sorensen, M.D. (“Dr. Sorensen”) to the Board of Directors (the “Board”) and to serve as the Company’s Executive Vice President and Chief Science Officer, with such appointment effective August 8, 2023.
On August 4, 2023, the Company appointed Dr. Gregory Sorensen, M.D. (“Dr. Sorensen”) to the Board of Directors (the “Board”) and to serve as the Company’s Executive Vice President and Chief Science Officer, with such appointment effective August 8, 2023.
Ruth V. Wilson did not to stand for re-election to the Board of Directors of RadNet, Inc. (the “ Company ”) at the Company’s Annual Meeting of Stockholders held on June 7, 2023 (the “ Annual Meeting ”).
Max materiality 0.85 · Median 0.70 · Most common event earnings